BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its ...

BridgeBio Pharma’s stock jumped more than 6% on Thursday after the drugmaker announced promising sales results for its FDA-approved heart drug as part of its latest quarterly earnings release. The ...

Shares of BridgeBio Pharma BBIO climbed to a 52-week high of $93.42 on Thursday after rival AstraZeneca's AZN late-stage ...

BridgeBio Pharma recently reported multiple developments, including new post-hoc analyses in Circulation: Heart Failure ...

BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

BBIO’s Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. This candidate positions BBIO against Pfizer’s Tafamidis and Alnylam’s Amvuttra. Its US uptake keeps ...

AstraZeneca and Ionis missed a key heart-drug trial goal, shifting attention to BridgeBio’s approved ATTR-CM treatment.

A BridgeBio Pharma drug developed for an increasingly prevalent cardiovascular condition has won FDA approval, marking a comeback for a company and a molecule with a turbulent history. But BridgeBio’s ...

Whoever says the Food and Drug Administration is too cozy with Big Pharma isn’t paying attention to the bonanza of new treatments launched by biotech startups. Late last week the FDA approved ...